Biogen Gives Up On Gosuranemab After No Benefit Seen In Alzheimer's Study
Phase II TANGO Trial Was Targeting Anti-Tau For Early Disease
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.
